NCT03598998 2025-06-26Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell LymphomasCity of Hope Medical CenterPhase 1/2 Active not recruiting13 enrolled 12 charts
NCT03035331 2025-05-16Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin LymphomaMayo ClinicPhase 1/2 Completed11 enrolled 12 charts
NCT02650999 2021-07-22Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory LymphomasAbramson Cancer Center at Penn MedicinePhase 1/2 Completed12 enrolled 8 charts
NCT02501473 2020-09-09MK-3475-174Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 1/2 Terminated52 enrolled 23 charts